AAV | Jotup

Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming

Retrieved on:

Thursday, February 22, 2024

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.

Key Points:

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.
While aging cannot be prevented, interventions targeting cellular processes offer potential for mitigating its impact on health and lifespan in the elderly.
Rejuvenate Bio's research focuses on partial reprogramming using the Yamanaka factors, specifically OCT4, SOX2, and KLF4 (OSK), to reverse age-related changes.
These results may have important implications for the development of partial reprogramming interventions to reverse age-associated diseases in the elderly population.”

KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer

Retrieved on:

Wednesday, February 21, 2024

Biotechnology, Pharmaceutical, Health, Oncology, Therapy, CMO, Potyvirus, Immunotherapy, Hematology, Growth, GM, AKA, Bladder cancer, Patient, Internal medicine, AAV, Lentivirus, Pharmaceutical industry

KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of industry leader James M. Burke, M.D., as Chief Medical Officer (CMO) to further advance its vision of providing patients with truly life changing cancer therapeutics by leveraging its next generation oncolytic virus platform.

Key Points:

KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of industry leader James M. Burke, M.D., as Chief Medical Officer (CMO) to further advance its vision of providing patients with truly life changing cancer therapeutics by leveraging its next generation oncolytic virus platform.
Dr. Burke brings over 20 years of global development experience in immuno-oncology.
“We are thrilled to welcome Dr. Burke to our team as we bring our pipeline of multi-mechanistic oncolytic virus programs into the clinic,” said Helena Chaye, Ph.D., J.D., Chief Executive Officer of KaliVir.
Previously, Dr. Burke was Chief Medical Office at Sillajen, Jennerex and Turnstone Biologics.

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

Retrieved on:

Thursday, March 7, 2024

Plasmid, Investment, Growth, Transfection, Series, LVV, CGT, Patient, AAV, Vaccine

SHENZHEN, China, March 7, 2024 /PRNewswire/ -- Shenzhen Eureka Biotechnology Co., Limited (EurekaBio), a leading upstream supplier in the cell and gene therapy field, announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from U.S. funds.

Key Points:

EurekaBio's core innovation lies in the EuLV™ Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system.
In contrast to traditional transient transfection production methods, the EuLV™ Lentiviral Vector Production System eliminates the necessity for plasmids, resulting in cost savings related to plasmid production and streamlining the overall production process.
Moreover, the EuLV™ system adopts a high-density suspension culture, which substantially increases unit titer levels, reduces production batches and associated costs and meets the requirements of large-scale lentiviral vector production.
The EuLV™ system presents a next-generation solution for lentiviral vector production to power cell and gene therapies, and is also well positioned for global adoption.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on:

Wednesday, March 6, 2024

Doctor of Philosophy, University of Massachusetts, Capsid, Microbiology, Transgene, Genetic, GEN, Dicarboxylic acid, Data analysis, Protein, Patient safety, Heart, Mary Ann Liebert, QC, AAV, Research, SBS, Workflow, Vaccine

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points:

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
"The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
"NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

Retrieved on:

Wednesday, February 28, 2024

Bangladesh Technical Education Board, FNIH, NPHP5, NIH, FDA, Partnership, Food, Bespoke Gene Therapy Consortium, AMP, CDMO, Organization, Associate, Patient, Disease, AAV, Pharmaceutical industry

COLUMBUS, Ohio, Feb. 28, 2024 /PRNewswire/ -- Andelyn Biosciences, Inc. , a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies in its suspension platform for several programs under the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC).

Key Points:

COLUMBUS, Ohio, Feb. 28, 2024 /PRNewswire/ -- Andelyn Biosciences, Inc. , a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies in its suspension platform for several programs under the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC).
BGTC has chosen to focus on eight rare disease programs , with Andelyn selected to optimize and scale the AAV therapy processes for the treatments of CNGB1 Retinitis Pigmentosa 45 and NPHP5 retinal degeneration.
Matt Niloff, Chief Commercial Officer of Andelyn, commented, "As a long-standing pioneer in AAV gene therapies with a focus on patients, we have great synergies with the BGTC.
With exceptional quality and scalable end-to-end development and manufacturing capabilities across its three Columbus, Ohio facilities, Andelyn is enabling the progression of life-altering gene therapies for rare and prevalent diseases.

Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers

Retrieved on:

Wednesday, February 28, 2024

Therapy, Acquisition, Engineering, Pfizer, Messenger, Library, UTR, RNA, Medicine, AAV, DNA, Vaccine

Instead, Ginkgo provides R&D services to customers who are looking to innovate across industries, including many world-class partners in biopharma.

Key Points:

Instead, Ginkgo provides R&D services to customers who are looking to innovate across industries, including many world-class partners in biopharma.
Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Patch has built an excellent team and platform which we are excited to welcome to Ginkgo.
Integrating Patch's capabilities, libraries, and datasets is immediately valuable to our on-going programs and augments the genetic medicine toolkit we have built for our customers.
JB Michel, CEO and co-founder of Patch Biosciences: "Joining Ginkgo Bioworks represents an exciting step in our journey to engineer better genetic medicines.

Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers

Retrieved on:

Wednesday, February 28, 2024

Proof was founded by gene editing pioneer Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs.

Key Points:

Proof was founded by gene editing pioneer Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs.
Gene editing systems have revolutionized the therapeutics industry, enabling a vast array of potential programmable medicines.
Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Ginkgo is committed to building world-class capabilities in engineering genetic medicines.
Integrating Proof's technologies and libraries gives our customers a new tool to overcome the limitations of current gene editing systems.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on:

Thursday, February 15, 2024

NINDS, Central nervous system, Rush University Medical Center, Giant axonal neuropathy, GM2, Rett syndrome, CNS, IP, GAN, IND, AAV, DSM-IV codes, Pharmaceutical industry

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points:

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
Taysha has been working to find ways to advance its deprioritized programs.
On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
“Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

Parent Project Muscular Dystrophy Provides $500,000 in Funding to Kinea Bio Through PPMD Venture Pathways Program to Support Next-Gen Midi-Dystrophin Gene Therapy Development

Retrieved on:

Tuesday, February 13, 2024

Gene, Doctor of Philosophy, Genetic disorder, Quality of life, DMD, Duchenne muscular dystrophy, Risk, Health, Protein, Patient, Knowledge, B cell, Male, PPMD, AAV, Vaccine

WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.

Key Points:

WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , is excited to announce that PPMD has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization's venture philanthropy program which provides industry funding to accelerate therapeutic development.
The organization prioritizes research for next-generation and future-generation gene therapies both through PPMD's Gene Therapy Initiative and the PPMD Venture Pathways program.
Casey Childers, DO, PhD, Chief Executive Officer of Kinea Bio, explains:
"We are pleased to receive this funding commitment from PPMD.
In addition to PPMD's significant pre-clinical and academic research funding, the organization provides funding to biopharmaceutical companies through PPMD Venture Pathways, its venture philanthropy program.

Freeline Shareholders Approve Acquisition by Syncona

Retrieved on:

Monday, February 12, 2024

Acquisition, Court, Company register, Scheme, High court, Proxy, Therapy, Patient, Environment, Gaucher, Gaucher's disease, Mass meeting, AAV

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”).

Key Points:

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”).
The resolution was passed by the requisite majority of Freeline shareholders and was accordingly passed.
Chris Hollowood, CEO of Syncona Investment Management Limited, said: “We are delighted our proposal to acquire Freeline has been approved by the required majority of Freeline shareholders.
We believe the acquisition by Syncona, which will result in Freeline becoming a private company, provides the best path forward for us to do that in this current environment, and we are grateful for the overwhelming support shown by our shareholders.”